Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
Official clinical guidance from the Movement Disorder Society providing an evidence-based biological definition, staging system, and classification framework for Parkinson's disease. This statement establishes standardized diagnostic and prognostic criteria for specialists managing the condition.
This longitudinal study tracked 258 newly diagnosed Parkinson's disease patients over five years, identifying three cognitive trajectory groups: cognitively normal, remitting decline, and progressive decline. Progressive cognitive decline was associated with depression, REM sleep behavior disorder, older age, lower education, elevated neurofilament biomarkers, and accelerated hippocampal volume loss, while remitting decline showed intermediate outcomes and olfactory dysfunction.
Researchers developed a screening tool to improve timely referral of Parkinson's disease patients to specialized centers for device-aided therapies, based on analysis of 259 patients across 8 hospitals. The tool identified response fluctuations and dyskinesias as key predictors and outperformed existing 5-2-1 referral criteria in clinical decision-making.
A study of 486 LRRK2-PD and 9,259 idiopathic PD patients found that higher mitochondrial polygenic scores (related to mitochondrial function genes) were significantly associated with earlier disease onset in LRRK2-PD carriers. The research identified meaningful interactions between genetic risk and lifestyle factors (caffeinated soda in LRRK2-PD, tobacco use in idiopathic PD), suggesting that disease timing may be influenced by both genetic and modifiable environmental factors.
This research explores metabotropic glutamate receptors (mGluRs) as potential therapeutic targets for managing Parkinson's disease symptoms. The approach focuses on modulating glutamatergic signaling pathways to address motor dysfunction and neurodegeneration associated with the condition.